Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 5/20 | 0.47 |
| ▸ | KDR | P35968 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | GOT1 | P17174 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | MPO | P05164 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | THPO | P40225 | 1/20 | 0.43 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.43 |
| ▸ | ACOX1 | Q15067 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29684247 | 0.85 | EGFR (0.53) | EGFRKDRALDH1A1LMNARAB9A | |
| SCHEMBL354115 | 0.85 | EGFR (0.53) | EGFRKDRALDH1A1LMNARAB9A | |
| SCHEMBL14993997 | 0.83 | ALDH1A1 (0.47) | EGFRKDRALDH1A1LMNARAB9A | |
| SCHEMBL27930312 | 0.81 | ALDH1A1 (0.46) | EGFRKDRALDH1A1LMNARAB9A | |
| SCHEMBL9584154 | 0.81 | EGFR (0.50) | EGFRKDRALDH1A1LMNARAB9A | |
| SCHEMBL28194071 | 0.81 | EGFR (0.42) | EGFRKDRALDH1A1LMNARAB9A | |
| SCHEMBL28279906 | 0.81 | EGFR (0.49) | EGFRKDRALDH1A1LMNARAB9A | |
| SCHEMBL9738820 | 0.80 | ALDH1A1 (0.49) | EGFRKDRALDH1A1LMNARAB9A | |
| SCHEMBL29617978 | 0.80 | ALDH1A1 (0.49) | EGFRKDRALDH1A1LMNARAB9A | |
| SCHEMBL30075136 | 0.78 | EGFR (0.49) | EGFRKDRALDH1A1LMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 204 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-7173145-A | — | — | None | — | — | JP | disclosed |
| JP-64003173-A | — | — | None | — | — | JP | disclosed |
| JP-4234321-A | — | — | None | — | — | JP | disclosed |
| JP-2009867-A | — | — | None | — | — | JP | disclosed |
| EP-2593456-B1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | UNIV COLUMBIA (US) | 2016-11-30 | — | — | EP | disclosed |
| EP-2654749-A2 | METHODS FOR TREATING COPD | The Board of Regents of The University of Texas System (US) | 2013-10-30 | — | — | EP | disclosed |
| US-20120270912-A1 | Substituted Indolealkanoic Acids | JONES MICHAEL LEE (US) | 2012-10-25 | — | — | US | disclosed |
| WO-2012088525-A2 | METHODS FOR TREATING COPD | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-06-28 | — | — | WO | disclosed |
| US-8163932-B2 | Substituted indolealkanoic acids | ALINEA PHARMACEUTICALS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20120065203-A1 | Methods of Reducing Serum Glucose and Triglyceride Levels and for Inhibiting Angiogenesis Using Substituted Indolealkanoic Acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2012-03-15 | — | — | US | disclosed |
| EP-0313202-A2 | Process for preparing halomethyl thiazoles | PFIZER INC. (US) | 1989-04-26 | — | — | EP | disclosed |
| JP-S643173-A | PREPARATION OF OXOPHTHALAZINYL-ACETIC ACID HAVING HETEROCYCLIC SIDE CHAIN SUCH AS BENZOTHIAZOLE | PFIZER INC | 1989-01-06 | — | — | JP | disclosed |
| CN-88103507-A | Process for the preparation of oxo-2, 3-naphthyridineacetic acids with benzothiazole or other heterocyclic branches | — | 1988-12-28 | — | — | CN | disclosed |
| CN-88103507-A | Process for the preparation of oxo-2, 3-naphthyridineacetic acids with benzothiazole or other heterocyclic branches | — | 1988-12-28 | — | — | CN | disclosed |
| EP-0295051-A2 | Preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains | PFIZER INC. (US) | 1988-12-14 | — | — | EP | disclosed |
| EP-0295051-A2 | Preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains | PFIZER INC. (US) | 1988-12-14 | — | — | EP | disclosed |
| EP-0295051-A2 | Preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains | PFIZER INC. (US) | 1988-12-14 | — | — | EP | disclosed |
| EP-0222576-A2 | Heterocyclic oxophthalazinyl acetic acids | PFIZER INC. (US) | 1987-05-20 | — | — | EP | disclosed |
| EP-0222576-A2 | Heterocyclic oxophthalazinyl acetic acids | PFIZER INC. (US) | 1987-05-20 | — | — | EP | disclosed |
| EP-0222576-A2 | Heterocyclic oxophthalazinyl acetic acids | PFIZER INC. (US) | 1987-05-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065203-A1 | Methods of Reducing Serum Glucose and Triglyceride Levels and for Inhibiting Angiogenesis Using Substituted Indolealkanoic Acids | LIPG, PNLIP, LIPA | EGFR 422/4885KDR 28/4885ALDH1A1 513/4885 |
| US-20120270912-A1 | Substituted Indolealkanoic Acids | GPR119, AANAT, AADAT | EGFR 1538/4885KDR 3420/4885ALDH1A1 338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.